Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 2992-2998

  Siegel, Abby B ^a   Cohen, Emil I ^a   Ocean, Allyson ^a   Lehrer, Deborah ^a   Goldenberg, Alec ^a   Knox, Jennifer J ^a   Chen, Helen ^a   Clark Garvey, Sean ^a   Weinberg, Alan ^a   Mandeli, John ^a   Christos, Paul ^a   Mazumdar, Madhu ^a   Popa, Elizabeta ^a   Brown Jr , Robert S ^a   Rafii, Shahin ^a   Schwartz, Jonathan D ^a  

^a Och Spine at New York Presbyterian Hospitals

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOKINE; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ARTERY THROMBOSIS; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOLOGICAL ACTIVITY; BLEEDING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTRAST ENHANCEMENT; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFECT; EPISTAXIS; FATIGUE; FEMALE; HEMOPERITONEUM; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DISEASE; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING; ANIMAL; BLOOD; DISEASE FREE SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; MAGNETIC RESONANCE ANGIOGRAPHY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CHEMOKINE CXCL12; DISEASE-FREE SURVIVAL; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 46449091500     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.9947     Document Type: Article

References (19)

1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576, 2007
2. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999
3. El-Serag HB, Davila JA, Petersen NJ, et al: The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 139:817-823, 2003
4. Llovet J, Ricci S, Mazzaferro V, et al: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 25:1s, 2007 (suppl; abstr LBA1)
5. Yamaguchi R, Yano H, Iemura A, et al: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68-77, 1998
6. Park YN, Kim YB, Yang KM, et al: Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124:1061-1065, 2000
7. Pang R, Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242:151-167, 2006
8. Thomas MB, Abbruzzese JL: Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23:8093-8108, 2005
9. Semela D, Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol 41:864-880, 2004
10. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
11. Jubb AM, Hurwitz HI, Bai W, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24:217-227, 2006
12. Schwartz JD, Sung M, Schwartz M, et al: Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 10:718-727, 2005
13. Pijl ME, Doornbos J, Wasser MN, et al: Quantitative analysis of focal masses at MR imaging: A plea for standardization. Radiology 231:737-744, 2004
14. Wang B, Gao ZQ, Yan X: Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol 46:353-358, 2005
15. Schwartz J, Gabrilove J, Madeli J, et al: Circulating vascular endothelial growth factor (VEGF) and related cytokines in unresectable hepatocellular carcinoma (HCC). 1st Annual Proceedings of the International Liver Cancer Association, Barcelona, Spain, October 5-7, 2007 (abstr)
16. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
17. Thomas MB, Chadha R, Iwasaki K, et al: The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 25:214s, 2007 (suppl; abstr 4567)
18. Abou-Alfa G, Johnson J, Knox JJ, et al: Final results from a phase II randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. 5th Annual Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008 (abstr)
19. Zhu AX, Blaszkowsky LS, Ryan DP, et al: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898-1903, 2006